Stable X-crystal-shaped agomelatine tablet and preparation method thereof

A stable technology of agomelatine tablets, applied in the field of pharmaceutical preparations, can solve the problems of inconsistent drug bioavailability, accelerated agomelatine crystal form transformation, infringement, etc.

Active Publication Date: 2014-03-26
天津泰普制药有限公司
View PDF7 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0013] (2) Narrow selection of excipients: commonly used excipients such as microcrystalline cellulose and pregelatinized starch are not available, mainly because the above excipients can accelerate the transformation of agomelatine crystal form;
[0016] The change of crystal form may cause infringement on the one hand, and may further lead to inconsistencies in the bioavailability of drugs on the other hand

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Stable X-crystal-shaped agomelatine tablet and preparation method thereof
  • Stable X-crystal-shaped agomelatine tablet and preparation method thereof
  • Stable X-crystal-shaped agomelatine tablet and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0140] Agomelatine (Form X 99%) 25g

[0141] water 20ml

[0142] Lactose 102g

[0143] Hypromellose 3g

[0144] Polyvinylpyrrolidone k30 3g

[0145] Cross-linked polyvinylpyrrolidone 13g

[0146] Magnesium Stearate 1.3g

[0147] Stearic acid 2.6g

[0148] Silica 0.3g

[0149] Process: Sift crystalline form X agomelatine according to the above weight for later use; take hydroxypropyl methylcellulose and polyvinylpyrrolidone k30 and stir in water to dissolve, let cool to room temperature, add crystalline form X agomelatine and stir homogeneous; the protective agent containing crystalline X-type agomelatine was obtained for later use; the protective agent containing crystalline X-type agomelatine was added to the mixed granulation containing lactose and part (1 / 2) cross-linked polyvinylpyrrolidone In the machine, after 2 minutes of wet granulation, granulate through a swing granulator (screen 833μm); get wet granules; dry in a fluidized bed (inlet air temperature 45°C, boi...

Embodiment 2

[0151] Agomelatine (more than 90% crystal X) 25g

[0152] water 30ml

[0153] Lactose 102g

[0154] Hydroxypropyl Cellulose 4.5g

[0155] Polyvinylpyrrolidone k30 4.5g

[0156] Croscarmellose Sodium 13g

[0157] Magnesium Stearate 1.3g

[0158] Stearic acid 2.6g

[0159] Silica 0.3g

[0160] Process: Sieve agomelatine crystal X according to the above weight for later use; take hydroxypropyl cellulose and polyvinylpyrrolidone k30 and stir in water to dissolve, let cool to room temperature, add agomelatine crystal X and stir well ; Obtain the protective agent containing crystal X-type agomelatine for later use; add the protective agent containing crystal X-type agomelatine to the mixture containing lactose and part (1 / 2) croscarmellose sodium In the granulator, after 2 minutes of wet granulation, granulate through a swing granulator (screen 833μm); get wet granules; dry in a fluidized bed (inlet air temperature 45°C, boiling bed temperature 30°C), control the moisture con...

Embodiment 3

[0162] Agomelatine (more than 85% crystal X) 25g

[0163] water 30ml

[0164] Lactose 102g

[0165] Hypromellose 4 .5g

[0166] Hydroxypropyl Cellulose 4.5g

[0167] Croscarmellose Sodium 13g

[0168] Magnesium Stearate 1.3g

[0169] Stearic acid 2.6g

[0170] Silica 0.3g

[0171]Process: Sift crystalline form X agomelatine according to the above weight for later use; take hydroxypropyl methylcellulose and polyvinylpyrrolidone k30 and stir in water to dissolve, let cool to room temperature, add crystalline form X agomelatine and stir homogeneous; the protective agent containing crystalline X-type agomelatine was obtained for later use; In the mixing granulator, after wet granulation for 2 minutes, granulate through a swing granulator (screen size 833 μm); wet granules are obtained; dry in a fluidized bed (inlet air temperature 45°C, boiling bed temperature 30°C), control the moisture content of about 2%; whole grain; calculate the yield, add other remaining excipients,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to view more

Abstract

The invention discloses a stable X-crystal-shaped agomelatine tablet and a preparation method thereof. The tablet is prepared by the following steps: selecting one or more protective agents, adding the protective agents in pure water, stirring, heating the mixture to 35-40 DEG C, dissolving until the solution is clear, cooling the solution to room temperature, adding X-crystal-shaped agomelatine, stirring the mixture uniformly, obtaining the protective agent containing the X-crystal shaped agomelatine, and keeping for standby use; mixing a part of pharmaceutic adjuvant uniformly, adding the protective agent containing the X-crystal-shaped agomelatine, mixing and pelletizing according to a wet method and drying to obtain particles containing the X-crystal-shaped agomelatine; at last, adding the other pharmaceutic adjuvants in the particles according to a proportion, mixing uniformly and tabletting. The preparation method can fully ensure that the crystal form of the X-crystal-shaped in the tablet preparation process is not changed; the stability between the X-crystal-shaped and the related substance is good to completely meet demand of large-scale production.

Description

[0001] technical field [0002] The invention belongs to the technical field of pharmaceutical preparations, and relates to a crystal X-form agomelatine tablet and a preparation method thereof. Background technique [0003] Agomelatine - a melatonin-like psychiatric drug. The melatonin analogue, agomelatine, is not only the first melatonin receptor agonist, but also a 5-hydroxytryptamine 2C (5-HT2C) receptor antagonist. Animal experiments and clinical studies have shown that the drug has the effects of antidepressant, anti-anxiety, regulating sleep rhythm and regulating the biological clock. At the same time, it has few adverse reactions, no adverse effects on sexual function, and no drug withdrawal reaction. [0004] The first melatonin receptor agonist, agomelatine (Valdoxan), is a melatonin analog, which is also a 5-hydroxytryptamine 2C (5-HT2C) receptor antagonist. The affinity Ki of melatonin to its receptors MT1 and MT2 is 8.85x10 -11 and 2.63x10 -11 , similar to a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/20A61K31/165A61K47/38A61K47/32A61P25/24A61P25/22A61P25/00
CPCA61K9/2027A61K9/2054C07C233/22C07B2200/13A61K9/2077A61K31/165A61K9/2095A61K9/2013A61K9/2018A61K9/2009A61P25/00A61P25/22A61P25/24
Inventor 周世旺代奕安适之赵健
Owner 天津泰普制药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap